FDA sees promise in Alzheimer's imaging drug
A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical designed to help screen for Alzheimer's disease could be useful pending additional study and training for physicians. The Food and Drug Administration panel of advisers voted 16-0 in favor of approval for Eli Lilly's Amyvid on the condition that the company demonstrates the images can be consistently interpreted by physicians who have received training in reading the scans. Without those requirements the panel voted 13-3 against approval for the injection in an earlier vote. The FDA is not required to follow the panel's advice, though it often does.
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Transforming Cancer Care
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Acute Kidney Injury Gets New Focus
- Interventional Radiology No Longer a Sub-Specialty
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- Sharp HealthCare Leaves Pioneer ACO Program
- mHealth Tackles Readmissions
- Proton Beam Therapy Poised for Growth in US
- MA an Insurance Proving Ground for Providers